SNWV

This article first appeared on GuruFocus. Revenue: $9.6 million for Q1 2026, a 3% increase from $9.3 million in Q1 2025. Gross Margin: 77.3% for Q1 2026, a decrease of 177 basis points year-over-year. Operating Loss: $1.1 million for Q1 2026, compared to an operating income of $0.6 million in Q1 2025. Operating Expenses: $8.6 million for Q1 2026, up from $6.8 million in Q1 2025. Net Loss: $1.4 million for Q1 2026, an improvement from a net loss of $6.1 million in Q1 2025. EBITDA: Negative $0.6 million for Q1 2026. Adjusted EBITDA: Positive $1.1 million for Q1 2026, down from $2.3 million in Q1 2025. Cash and Cash Equivalents: $10.8 million as of March 31, 2026. Active Systems: Increased to 1,382 from 1,292 at year-end 2025. Consumables Utilization: Grew 22% year-over-year and 4% sequentially from Q4 2025. Warning! GuruFocus has detected 8 Warning Signs with SNWV. Is SNWV fairly valued? Test your thesis with our free DCF calculator. Release Date: May 13, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. SANUWAVE Health Inc (NASDAQ:SNWV) achieved the highest Q1 revenues in company history, surpassing the previous year's record by 3%. Consumables utilization grew by 22% year-over-year and 4% sequentially from Q4 2025, indicating strong demand. The company sold 97 systems in Q1, increasing the number of active systems to 1,382 from 1,292 at year-end. There is renewed interest and progress in mobile wound care, with SANUWAVE Health Inc (NASDAQ:SNWV) seeing opportunities in long-term care and nursing facilities. The company is experiencing increased engagement from large systems, which could lead to significant growth opportunities in the second half of the year. The advanced wound care market experienced a shock pause in January due to unexpected CMS pricing changes, affecting initial performance. Gross margin decreased by 177 basis points year-over-year, primarily due to a shift to wholesale pricing for resellers. Operating loss for Q1 2026 was $1.1 million, a significant swing from the operating income of $0.6 million in the same period last year. Operating expenses increased by $1.8 million year-over-year, driven by higher non-cash stock-based compensation, payroll, and R&D expenses. The rural market poses challenges due to lower pay rates and high travel costs, which may require re-indexing or payment ad...

Interested in Sanuwave Health Inc.? Here are five stocks we like better. Sanuwave posted record first-quarter revenue of $9.6 million, up 3% year over year, as consumables utilization rose 22% and Active Systems increased to 1,382. Management said the advanced wound care market began recovering after a January slowdown tied to new CMS reimbursement changes. Margins and operating results were pressured by wholesale/reseller mix and higher spending. Gross margin fell to 77.3%, operating expenses rose to $8.6 million, and the company reported a $1.1 million operating loss, though net loss improved sharply from a year ago because prior one-time derivative and interest expenses did not repeat. Management kept full-year 2026 guidance unchanged at $51 million to $55 million and expects second-quarter revenue growth of 10% to 15%. CEO Morgan Frank said the company is seeing stronger hospital, long-term care and national account interest, and still expects a stronger second half of the year. 3 Lesser-Known Healthcare Names With Major Upside in Store Sanuwave Health (NASDAQ:SNWV) reported record first-quarter revenue and rising consumables utilization, while management said the advanced wound care market began to recover after a difficult start to the year tied to changes in reimbursement for skin substitutes. Chairman and CEO Morgan Frank said the first quarter of 2026 began with what he described as a “shock pause” in January, as the advanced wound care market “seemed to sort of lock up for a moment.” He said many market participants appeared to have expected that new CMS pricing for skin substitutes would be rescinded or modified before taking effect, which did not happen. → Rocket Lab Just Hit a New All-Time High—Time to Buy or Let It Breathe? “It took the market a little time to come to terms with this, but at least from where we sit, it seems to have started doing so in February,” Frank said. He added that Sanuwave saw improvement throughout the quarter, with each month better than the prior month. CFO Peter Sorensen said revenue for the three months ended March 31, 2026, totaled $9.6 million, up 3% from $9.3 million in the same period of 2025. He said the result marked the highest first-quarter revenue in company history, though it came in at the low end of the company’s guidance range for 3% to 10% growth. → MercadoLibre Boldly Invests in Growth: Discount Deep...

Q1 2026 revenues were $9.6 million, up 3.1% from $9.3 million in Q1 2025. This represents the highest Q1 quarterly revenues in Company history. Q1 2026 gross margin was 77.3%, versus 79.0% in Q1 2025. GAAP Operating Loss was $1.1 million for Q1 2026, a swing of $1.7 million from operating income of $0.6 million in Q1 2025. Company provides guidance for revenue growth of 10-15% for Q2 2026 as compared to Q2 2025 EDEN PRAIRIE, Minn., May 12, 2026 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave”) (NASDAQ: SNWV), a leading provider of next-generation FDA-approved wound care products, is pleased to provide its financial results for the three months ended March 31, 2026. Q1 2026 ended March 31, 2026 Revenue for the three months ended March 31, 2026, totaled $9.6 million, an increase of 3.1%, as compared to $9.3 million for the same period of 2025. This growth is consistent with guidance of 3-10% year on year for the quarter. 97 Ultramist® systems were sold in Q1 2026 down from 98 in Q1 2025, and down from 255 in Q4 2025. Ultramist® consumables revenue increased by 15.0% to $6.7 million in Q1 2026, versus $5.8 million for the same quarter last year and increased 3% sequentially vs Q4 2025. Ultramist® revenue represented 100% of Sanuwave’s overall revenues in Q1 2026. Gross margin as a percentage of revenue amounted to 77.3% for the three months ended March 31, 2026, versus 79.0% for the same period last year. This decrease in gross margin as a percentage of revenue was largely driven by a decrease in pricing on our Ultramist® systems and applicators resulting from wholesale pricing for sales to resellers. For the three months ended March 31, 2026, operating loss totaled $1.1 million, a $1.7 million swing from operating income of $0.6 million in Q1 2025. Net loss for the first quarter of 2026 was $1.4 million compared to a net loss of $6.1 million in the first quarter of 2025, which was primarily driven by the $4.9 million non-cash loss on the change in fair value of derivative liabilities recognized in the prior year period. Adjusted EBITDA [1] for the three months ended March 31, 2026, was $1.1 million versus Adjusted EBITDA of $2.3 million for the same period last year. “The seemingly ubiquitous question in advanced wound care during Q1 was ‘When is the turn coming and when will the recovery start?’” said CEO Morgan Frank. “Speaking for Sanu...

SANUWAVE Health Inc (OTC:SNWV) released first-quarter financial results and hosted an earnings call on Wednesday. Read the complete transcript below. This transcript is brought to you by Benzinga APIs. For real-time access to our entire catalog, please visit https://www.benzinga.com/apis/ for a consultation. The full earnings call is available at https://viavid.webcasts.com/starthere.jsp?ei=1762392&tp_key=537d7338d6 SANUWAVE Health Inc reported record Q1 revenues of $9.6 million, a 3% increase from the previous year, driven by a 22% year-over-year increase in consumables utilization. The company saw a rise in active systems to 1382, up from 1292 at year-end, despite initial market challenges due to new CMS pricing for skin substitutes. Guidance for Q2 is set at 10-15% year-over-year growth, with a full-year target of $51 to $55 million, supported by increased engagement with large systems and potential expansion into new market areas. Operational loss for Q1 was $1.1 million, with increased expenses in R&D, sales, and marketing, but a significant reduction in net loss from $6.1 million to $1.4 million year-over-year. The company is focusing on maintaining operational discipline, expanding the adoption of Ultramist, and addressing challenges in rural healthcare delivery. OPERATOR Hello and welcome everyone joining today's SANUWAVE Health Inc earnings call. At this time all participants are in a listen only mode. Later you will have the opportunity to ask questions during the question and answer session. To register to ask a question at any time, please press star 1 on your telephone keypad. Please note this call is being recorded. We are standing by if you should need any assistance. It is now my pleasure to turn the meeting over to Morgan Frank, Chairman and CEO of SANUWAVE Health Inc. Please go ahead. Morgan Frank (Chairman and CEO) Thank you Nikki welcome to SANUWAVE Health Inc's first quarter 2026 earnings call. Our Form 10Q was filed with the SEC last night along with our earnings release and our updated presentation was made available on our website in the Investor section. Please refer to that during the presentation. Joining me on the call is Peter Sorensen, our CFO and after the presentation we will open up for Q&A. So let's begin with the forward looking statements and disclosures. This call may contain forward looking statements such as statements...

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here. Management characterized January as a 'shock pause' where the advanced wound care market froze due to anticipated CMS pricing changes for skin substitutes that were not rescinded. Market recovery began in February, with sequential monthly improvements throughout the quarter as practitioners adapted to the new reimbursement reality. Record applicator unit sales were driven by a net increase of 90 active systems and recovering usage rates, though revenue growth was tempered by a shift toward wholesale pricing for resellers. The company is observing a consolidation in the mobile wound care space, where lower allograft reimbursement is forcing smaller providers to merge to cover high back-office and practitioner costs. Management maintains that the 'care to the edge' philosophy remains vital, as patients in mobile settings are often unable to travel to traditional wound centers. Strategic focus is expanding into hospitals and long-term care facilities, with hospitals showing particular strength as providers seek more holistic patient care models. Q2 guidance of 10% to 15% growth assumes continued recovery from the 'market freeze' and increased clarity regarding CMS skin substitute audits and clawbacks. Full-year guidance of $51 million to $55 million is maintained, predicated on a historical seasonal trend where the second half typically increases 48% over the first half. Management expects the second half of 2026 to outperform typical seasonality due to significant engagement and ongoing evaluations with several large national health systems. R&D spending has returned to normalized levels to support incremental product improvements, line extensions, and expansion into adjacent clinical areas over the next 24 months. Future growth is expected to be supported by upcoming white papers and clinical data validating UltraMIST's cost-effectiveness and utility in novel use cases. The company has entered into voluntary disclosure agreements with most applicable states to resolve sales tax exposure, aiming to limit look-back periods and abate penalties. Operating expenses increased by $1.8 million year-over-year, driven by higher headcount, R&D investments, and $300,000 in nonrecurring restatement and legal fees. Managem...

EDEN PRAIRIE, Minn., May 06, 2026 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave”) (NASDAQ: SNWV), a leading provider of next-generation FDA-approved wound care products, will host a live conference call on Wednesday, May 13, 2026, at 8:30 AM (ET) to present its Q1 2026 financial results. Telephone access to the call will be available by dialing the following numbers: Participant Dial-in Information Toll Free: 1-833-316-1983 Toll/International: 1-785-838-9310 Conference ID: SANUWAVE OR click the link below to access the live webcast: https://viavid.webcasts.com/starthere.jsp?ei=1762392&tp_key=537d7338d6 Materials for the conference call will be included on the Company’s website at www.sanuwave.com/investors. A replay will be made available through Wednesday, May 27, 2026: Toll-Free: 1-844-512-2921 or 1-412-317-6671 Replay Access ID: 11161765 About Sanuwave Sanuwave Health is focused on the research, development, and commercialization of its patented, non-invasive and biological response-activating medical systems for the repair and regeneration of skin, musculoskeletal tissue, and vascular structures. Sanuwave's end-to-end wound care portfolio of regenerative medicine products and product candidates help restore the body’s normal healing processes. Sanuwave applies and researches its patented energy transfer technologies in wound healing, orthopedic/spine, aesthetic/cosmetic, and cardiac/endovascular conditions. Forward-Looking Statements This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to future financial results, production expectations, plans for future business development activities and expectations regarding the impact of changes in tariff rates. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the key risks, assumptions and factors that may affect operating results, performance and f...

biote Corp. (BTMD) came out with quarterly earnings of $0.06 per share, missing the Zacks Consensus Estimate of $0.09 per share. This compares to earnings of $0.08 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -33.33%. A quarter ago, it was expected that this company would post earnings of $0.05 per share when it actually produced earnings of $0.06, delivering a surprise of +20%. Over the last four quarters, the company has surpassed consensus EPS estimates three times. biote Corp., which belongs to the Zacks Medical - Products industry, posted revenues of $44.94 million for the quarter ended March 2026, missing the Zacks Consensus Estimate by 2.71%. This compares to year-ago revenues of $48.99 million. The company has topped consensus revenue estimates two times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. biote Corp. shares have lost about 15% since the beginning of the year versus the S&P 500's gain of 6%. While biote Corp. has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for biote Corp. was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here....

MacroGenics (MGNX) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2026. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price. The stock might move higher if these key numbers top expectations in the upcoming earnings report. On the other hand, if they miss, the stock may move lower. While management's discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations, it's worth having a handicapping insight into the odds of a positive EPS surprise. This biopharmaceutical company is expected to post quarterly loss of $0.56 per share in its upcoming report, which represents a year-over-year change of +13.9%. Revenues are expected to be $21.22 million, up 60.9% from the year-ago quarter. The consensus EPS estimate for the quarter has been revised 22.3% lower over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period. Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change. Price, Consensus and EPS Surprise Estimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. This insight is at the core of our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction). The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier. Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP reading...

Wall Street expects a year-over-year increase in earnings on higher revenues when Sanuwave Health Inc. (SNWV) reports results for the quarter ended March 2026. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates. The stock might move higher if these key numbers top expectations in the upcoming earnings report. On the other hand, if they miss, the stock may move lower. While management's discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations, it's worth having a handicapping insight into the odds of a positive EPS surprise. This company is expected to post quarterly loss of $0.05 per share in its upcoming report, which represents a year-over-year change of +92.4%. Revenues are expected to be $9.63 million, up 3.1% from the year-ago quarter. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period. Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change. Estimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. Our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction) -- has this insight at its core. The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier. Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only. A positive Earnings ESP is a strong predictor of an earnings beat...

Record Q4 revenue of $13.4 million was driven by a historic 255 UltraMIST system placements, despite significant volatility in the broader wound care sector. Management attributed industry-wide pressure to a 90-95% CMS reimbursement cut for skin substitutes, which triggered massive clawbacks and business closures for many of SANUWAVE's customers. The company sunset the dermaPACE and Profile product lines in Q4 to focus resources on the high-growth UltraMIST modality and improve operational focus. A strategic shift toward stocking distributors and resellers is underway to rapidly capture 'white space' left by competitors exiting the market. Management introduced an 'Active Systems' metric (1,292 units) to provide better resolution on actual utilization following the closure of several distressed customer accounts. The cost-effectiveness of UltraMIST is positioned as a primary competitive advantage as the market shifts toward evidence-based standards and lower-cost treatment alternatives. Q1 2026 revenue guidance of $9.6 million to $10.3 million reflects a temporary 'stutter step' as the industry recalibrates following regulatory shocks. Full-year 2025 revenue growth is projected at 16% to 25%, assuming a significant performance inflection in the second half of the year. The company is targeting a channel inventory range of 8 to 10 weeks for resellers, with plans to reduce this further through better ERP integration. New manufacturing initiatives for applicators are expected to begin producing product within months, potentially providing a multi-hundred basis point lift to gross margins over time. Expansion strategy relies on 'baby elephant' customers—newly formed provider groups that are scaling rapidly to fill the void left by dissolved mobile wound care entities. A $486,000 inventory write-off was recorded in Q4 associated with the strategic decision to discontinue the PACE product line. Financial restatements were completed to address $1.6 million in previously unrecognized sales tax liabilities identified through a Nexus study. Management flagged a '9-figure clawback' environment for practitioners using skin substitutes, which has created a climate of fear and documentation scrutiny among the customer base. The shift to wholesale pricing for resellers will lower reported Average Selling Prices (ASPs) but is expected to yield higher operating margins due t...

Record Q4 and full-year results: Sanuwave reported Q4 revenue of $13.4 million (up 30% YoY) and adjusted EBITDA of $4.8 million, driven by record system placements—624 UltraMIST systems sold in 2025 with a Q4 high of 255 systems. Industry disruption and new metric: Management introduced an “active systems” metric (1,292 at Q4) after a shift toward resellers and CMS reimbursement changes that, while not affecting UltraMIST coding, have reduced customer counts and led to 168 discontinued systems. Financial housekeeping and outlook: The company recorded a restatement mainly tied to sales-tax liabilities (about $1.6M) and a ~$300k revenue allocation error, finished the year with $12.0M in cash, and guided Q1 revenue to $9.6M–$10.3M with preliminary 2026 revenue growth of 16%–25% while withholding adjusted EBITDA guidance. Interested in Sanuwave Health Inc.? Here are five stocks we like better. 3 Lesser-Known Healthcare Names With Major Upside in Store Sanuwave Health (NASDAQ:SNWV) reported fourth-quarter and full-year 2025 results that management described as a “good if slightly complicated quarter,” highlighted by record revenue, record system placements, and sharply higher full-year profitability. Executives also spent significant time discussing how recent CMS reimbursement changes for skin substitutes and allografts are disrupting parts of the wound-care market, influencing customer behavior, and affecting the company’s growth outlook early in 2026. CEO Morgan Frank said the fourth quarter was an all-time record for the company, with revenue of $13.4 million, up 30% from the prior-year quarter, and adjusted EBITDA of $4.8 million, up from $3.7 million a year earlier. Adjusted EBITDA represented 36% of quarterly revenue, according to Frank. → Is Oracle the First of the AI Bubbles to Pop? For the full year, revenue rose 35% to $44.1 million. Full-year adjusted EBITDA increased 89% to $13.6 million from $7.2 million in 2024. Frank attributed the performance to growth in UltraMIST system placements and ongoing usage of consumables. System sales were a notable driver. The company sold 624 UltraMIST systems in 2025 compared with 374 in the prior year, and fourth-quarter sales reached 255 systems, which Frank said was the highest quarterly number in company history and exceeded the prior record set in the third quarter by 100 systems. During the Q&A, Frank said the...